Key facts
- This page summarizes Stephen Kanes's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Oct 2021, 16:02.
Stephen Kanes - 19 Oct 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- SAGE
- Reported as of
- 19 Oct 2021
- Net transaction value
- -$45,125
- SEC form
- 4
- Accepted by SEC
- 21 Oct 2021, 16:02:51 UTC
- Prior SEC filing
- 17 Jun 2021
- Next SEC filing
- 16 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Stephen Kanes
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Kanes filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 21 Oct 2021.
Change
- Previous filing in this sequence was filed on 17 Jun 2021.
- Current net transaction value: -$45,125.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +3,800
- Change %
- +35%
- Price
- $0.000000
- Shares after
- 14,591
- Date
- 19 Oct 2021
- Ownership
- Direct
- Footnotes
- F1
SAGE
transaction
Common Stock
Tax liability
- Transaction value
- $45,125
- Shares
- -1,120
- Change %
- -7.7%
- Price
- $40.29
- Shares after
- 13,471
- Date
- 19 Oct 2021
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On February 13, 2019, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 9,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on October 19, 2021, resulting in the vesting of the PSUs as to 3,800 shares.